M. López-Casla

The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients

E. Martı́n-Mola, C. Plasencia, A. Balsa, 2013, Arthritis Research & Therapy.

FRI0270 Does Immunogenicity Influence on Drug Survival of Anti-TNF?

E. Martı́n-Mola, C. Plasencia, A. Balsa, 2014 .

Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice

M. Nurmohamed, G. Wolbink, C. Plasencia, 2014, Annals of the rheumatic diseases.

Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.

F. Soriano, L. Alou, L. Huelves, 2006, International journal of antimicrobial agents.

The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab

E. Martı́n-Mola, C. Plasencia, A. Balsa, 2013, Annals of the Rheumatic Diseases.

AB0573 The immunogenicity of biological therapies correlates with clinical efficacy in psoriatic arthritis (psa) in long-term treatment with infliximab and adalimumab.

E. Martı́n-Mola, C. Plasencia, A. Balsa, 2013 .